Domiren 10: A Motility Stimulant and Anti-emetic

Domiren 10 contains Domperidone, a dopamine antagonist that acts as a prokinetic agent and anti-emetic. It is primarily used to address various dyspeptic symptoms and to prevent nausea and vomiting, particularly by influencing the upper gastrointestinal tract's motility.

How Domiren 10 Works (Pharmacology)

Domperidone is a dopamine antagonist that primarily blocks dopamine receptors located in the Chemoreceptor Trigger Zone (CTZ) and in the stomach.

• Gastroprokinetic action: Its action on dopamine receptors in the gastrointestinal tract restores normal motility and tone of the upper digestive system. This facilitates gastric emptying, enhances antral and duodenal peristalsis, and regulates pyloric contraction. It also increases esophageal peristalsis and lower esophageal sphincter pressure, preventing gastric content regurgitation.
• Anti-emetic action: By blocking dopamine receptors in the CTZ, it suppresses nausea and vomiting.
• Reduced CNS effects: Due to its weak penetration across the blood-brain barrier, Domperidone has minimal effect on dopaminergic receptors in the brain, which contributes to its low incidence of psychotropic and neurological side effects compared to other dopamine antagonists.

Key Indications & Benefits

Domiren is indicated for the treatment of various digestive discomforts and nausea/vomiting:

• Dyspeptic symptom complex, often associated with delayed gastric emptying, gastroesophageal reflux, and esophagitis, including:
  • Epigastric sense of fullness
  • Feeling of abdominal distension
  • Upper abdominal pain
  • Eructation (belching)
  • Flatulence
  • Early satiety (feeling full quickly)
  • Nausea and vomiting
  • Heartburn with or without regurgitations of gastric contents into the mouth
• Non-ulcer dyspepsia
• Acute nausea and vomiting of various origins (functional, organic, infectious, dietetic, or induced by radiotherapy, drug therapy, or migraine).
• Parkinson's disease: For dopamine-agonist induced nausea and vomiting.
• Radiological studies: To speed barium transit in follow-through radiological studies.

Dosage & Administration

Domperidone should be taken 15-30 minutes before meals and, if necessary, before retiring.

Usual Recommended Oral Dose:

• Adults: 10-20 mg (1-2 tablets or 10-20 ml suspension) every 6-8 hours daily. The maximum daily dose is 80 mg.
• Children: 2-4 ml suspension/10 kg body weight or 0.4-0.8 ml pediatric drops/10 kg body weight, every 6-8 hours daily.

In Dyspeptic Symptom:

• Adults: 10-20 mg (1-2 tablets or 10-20 ml suspension), every 6-8 hours daily.
• Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml pediatric drops/10 kg) body weight, every 6-8 hours daily.

In Acute and Sub-acute Conditions (mainly in acute nausea and vomiting):

• Adults: 20 mg (2 tablets or 20 ml suspension), every 6-8 hours daily.
• Children: 0.2-0.4 mg/kg (2-4 ml suspension/10 kg or 0.4-0.8 ml pediatric drops/10 kg) body weight, every 6-8 hours daily. (Maximum period of treatment for acute nausea and vomiting is 12 weeks).

By Rectum (Suppositories):

• Adults (including elderly): 30-60 mg every 4-8 hours.
• Children: The maximum daily rectal dose for children weighing 10 to 25 kg is 30 mg. The dose may be divided throughout the day if necessary.
• The maximum period of treatment is 12 weeks.

Always consult a registered physician for medication use.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Domiren 10.

Contraindications:

• Known hypersensitivity to Domperidone or in the case of neonates.
• Whenever gastrointestinal stimulation might be dangerous (e.g., gastrointestinal hemorrhage, mechanical obstruction, or perforation).
• Patients with prolactin-releasing pituitary tumor (prolactinoma).

Side Effects:

• Side effects are generally rare.
• Exceptional: Transient intestinal cramps.
• Rare: Extrapyramidal phenomena (involuntary movements) in young children and exceptional in adults; these are reversible upon stopping treatment.
• Endocrine effects (due to increased plasma prolactin): Galactorrhoea (milk production) and gynaecomastia (breast enlargement in males) may occur in rare cases.
• Neurological side effects: Cannot be totally excluded in infants where the blood-brain barrier is immature or impaired.
• Rare allergic reactions: Such as rash and urticaria.

Interactions:

• Anticholinergic drugs: Concomitant administration may antagonize the antidyspeptic effect of Domperidone.
• Antacids and antisecretory drugs: Should not be given simultaneously as they lower Domperidone's oral bioavailability.
• CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics, HIV protease inhibitors, nefazodone): Concomitant use may significantly increase plasma levels of Domperidone, potentially leading to increased risk of side effects (particularly cardiac rhythm disturbances, though not explicitly stated in this section for Domiren).
• Digoxin or paracetamol: Domperidone generally does not influence their blood levels.
• Neuroleptics: Domperidone does not potentiate their action.
• Dopaminergic agonists (e.g., bromocriptine, L-dopa): Domperidone suppresses their unwanted peripheral effects (digestive disorders, nausea, vomiting) without counteracting their central properties.

Pregnancy & Lactation:

• Pregnancy: Animal tests showed no teratogenic effects at high doses. However, due to insufficient human clinical evidence, Domperidone should only be used during the first trimester of pregnancy if the anticipated therapeutic benefit clearly justifies the potential risk. No evidence of increased risk of malformations in humans has been observed to date.
• Lactation: The drug is excreted in breast milk. Domperidone concentrations in breast milk are four times lower than corresponding plasma concentrations. It is not known whether this is harmful to the newborn. Therefore, nursing is not recommended for mothers taking Domperidone unless the expected benefits outweigh any potential risk.

Precautions & Warnings:

• Children: Use with absolute caution, especially in young children, due to an increased risk of extrapyramidal reactions because of an incompletely developed blood-brain barrier.
• Hepatic impairment: Use with caution as Domperidone is highly metabolized in the liver.
• Urine darkening: Patients should be warned that Domiren does not affect mental alertness or ability to drive/use machines (this note refers to effects on mental alertness, not urine). (The original text mentions "Patients should be warned that Dirozyl may darken urine." This might be a copy-paste error from another drug. For Domperidone, urine darkening is not a commonly reported side effect. The text specifically states "Domperidone does not affect the mental alertness." in this section).

Use in Special Populations:

• Infants: Use with great caution and under close medical supervision due to incompletely developed metabolic and blood-brain barrier functions. Neurological side effects cannot be totally excluded in infants under 1 year.
• Liver disorders: Use with caution in patients with hepatic impairment, as Domperidone is highly metabolized in the liver.
• Kidney disorders:
  • In severe renal insufficiency (serum creatinine >6 mg/100ml), the elimination half-life is increased, but plasma levels were lower than in healthy volunteers.
  • Single acute administration may not require dose adjustment.
  • However, for repeated administration, the dosing frequency should be reduced to once or twice daily, depending on severity, and the dose may need to be reduced. Patients on prolonged therapy should be regularly reviewed.

Overdose Effects:

• Symptoms may include drowsiness, disorientation, and extrapyramidal reactions, especially in children.
• Management: In case of overdose, activated charcoal administration and close observation are recommended. Anticholinergic, antiparkinson drugs, or antihistamines with anticholinergic properties may help control extrapyramidal reactions.

Storage Conditions

Store below 30°C, protected from light & moisture. Keep out of children's reach.